Liposome‐encapsulated chemotherapy: Current evidence for its use in companion animals

Abstract

Cytotoxic drugs encapsulated into liposomes were originally designed to increase the anticancer response, while minimizing off-target adverse effects. The first liposomal chemotherapeutic drug was approved for use in humans more than 20 years ago, and the first publication regarding its use in a canine cancer patient was published shortly thereafter. Regardless, no general application for liposomal cytotoxic drugs has been established in veterinary oncology till now.Due to the popularity of canines as experimental models for pharmacokinetic analyses and toxicity studies, multiple publications exist describing various liposomal drugs in healthy dogs. Also, some evidence for its use in veterinary cancer patients exists, especially in canine lymphoma, canine splenic hemangiosarcoma and feline soft tissue sarcoma, however, the results have not been overwhelming. Reasons for this may be related to inherent issues with the enhanced permeability and retention effect, the tumour phenomenon which liposomal drugs exploit. This effect seems very heterogeneously distributed in the tumour. Also, it is potentially not as ubiquitously occurring as once thought, and it may prove important to select patients for liposomal therapy on an individual, non-histology-oriented, basis. Concurrently, new developments with active-release modified liposomes in experimental models and humans will likely be relevant for veterinary patients as well, and holds the potential to improve the therapeutic response. It, however, does not resolve the other challenges that liposomal chemotherapy faces, and more work still needs to be done to determine which veterinary patients may benefit the most from liposomal chemotherapy. K E Y W O R D Schemotherapy, liposomes, nanomedicine, oncology, small animal

Cryo-EM sample preparation method for extremely low concentration liposomes

“…Liposomes are widely used as carrier systems in pharmaceutics (e.g. encapsulate therapeutic agents for cancer therapy (Børresen et al, 2018;Yuba, 2018;Zununi Vahed et al, 2017) and for neurological diseases (Vieira and Gamarra, 2016)), food industries (e.g. encapsulate bioactive food compounds to improve flavoring and nutritional properties or protect the food from spoilage and degradation (Shukla et al, 2017) ) and cosmetics (e.g.…”

Immunohistochemical Labeling of Low-Density Lipoprotein Receptor and Scavenger Receptor Class B Type 1 Are Increased in Canine Lymphoma

“…Lipid-encapsulation of drugs directs their delivery to LDL-R and other lipid-uptake receptors. Previous studies comparing lipid-encapsulated doxorubicin to the standard drug in canine lymphoma cases did not detect an appreciable difference (34). However, sample size was small and no selection criteria relative to lipid metabolism or expression of lipid uptake receptors was included.…”

Role of Oxidized Lipids in Permeation of H2O2 Through a Lipid Membrane: Molecular Mechanism of an Inhibitor to Promoter Switch

“…We are currently investigating how the molecular structure of the oxidized lipid affects the transition behaviour, the concentration at which the transition occurs, and the permeation ability. This technology opens new avenues for the development of novel methodology in drug delivery 46 and chemotherapy 47 that relies on selective permeation of drug molecules.…”